Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Agarwala, Sanjiv S., Ciliberto, Gennaro, Demaria, Sandra, Dummer, Reinhard, Duong, Connie P. M., Ferrone, Soldano, Formenti, Silvia C., Garbe, Claus, Halaban, Ruth, Khleif, Samir, Luke, Jason J., Mir, Lluis M., Overwijk, Willem W., Postow, Michael, Puzanov, Igor, Sondel, Paul, Taube, Janis M., Thor Straten, Per, Stroncek, David F., Wargo, Jennifer A., Zarour, Hassane, Thurin, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691855/
https://www.ncbi.nlm.nih.gov/pubmed/29145885
http://dx.doi.org/10.1186/s12967-017-1341-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691855/
https://www.ncbi.nlm.nih.gov/pubmed/29145885
http://dx.doi.org/10.1186/s12967-017-1341-2

Ejemplares similares